Clinical TrialAug 13, 2026, 05:04 PM
Satellos Bioscience Gets FDA Fast Track; Positive Phase 2 DMD Data
AI Summary
Satellos Bioscience received FDA Fast Track Designation for SAT-3247 for Duchenne muscular dystrophy (DMD). The company reported positive six-month follow-up data from its TRAILHEAD Phase 2 adult DMD study, showing reduced muscle fat, increased total effort, and improved quality of life, consistent with muscle regeneration. Enrollment is advancing in the BASECAMP Phase 2 pediatric study, with data expected in Q4 2026. Satellos also reported a strong cash position of $61.8 million, providing a runway through 2027, despite increased R&D and G&A expenses leading to a net loss of $11.7 million for Q2 2026.
Key Highlights
- SAT-3247 granted FDA Fast Track Designation for Duchenne muscular dystrophy (DMD).
- TRAILHEAD Phase 2 adult DMD study showed reduced muscle fat fraction and increased total effort at 6 months.
- BASECAMP Phase 2 pediatric DMD study clinical data expected in Q4 2026.
- Plans to submit IND for facioscapulohumeral muscular dystrophy (FSHD) and launch Phase 2 trial in H2 2026.
- Cash, cash equivalents, and short-term investments of $61.8 million as of June 30, 2026.
- Cash runway expected to provide funding through 2027.
- Net loss for Q2 2026 was $11.7 million ($0.56 loss per share).
- R&D expenses increased to $9.6 million for Q2 2026 from $4.4 million YoY.
Price Impact
More from MSLE